News

 Basel, Switzerland, July 10th, 2020. Swiss-based Orphanion supports small to mid-sized biotech and pharma companies with customized development, procurement and consulting services to optimize the growing sales potential for niche pharmaceuticals, orphan drugs and oligonucleotides. Guido Bossi, Managing Director, announced that “Orphanion is very pleased to announce that Bianca Matthee joined it’s Scientific Advisory Board. Bianca Matthee, a PharmD by training, has extensive international experience in chemistry, manufacturing and control (CMC) of oligonucleotides, but also other types of drug substances and drug products. Bianca has a distinguished career background in drug product formulations for various routes of administration, predominantly for niche indications, and was a core member of Dutch based ProQR Therapeutics acting as Vice President for Manufacturing and CMC.

 After Thomas Rupp, a recognized, world-class leading expert in oligonucleotides, joined Orphanion’s Scientific Advisory Board, we can now offer our clients a know-how base second to none in the growing market potential for new technologies and products in the field of oligonucleotides”. With the serious threat of COVID-19 threat to public health worldwide, Orphanion enhances its capabilities of the seamless access to the well-known immunostimulant oligonucleotide CPG7909. Originally developed in the field of oncology and due to its strong immunostimulatory effects, CpG7909 found several pharmaceutical applications and is also under development as an adjuvant for vaccines against cancer, infectious and various viral diseases.

 Orphanion will continue its efforts to provide highest quality - non-GMP and cGMP - combined with competitive pricing of its CpG ODN products in order to make a small contribution to accelerate development and manufacturing projects of effective therapies which can help to combat the unprecedented COVID-19 pandemic.

 The services comprise up-to-date, extensive and over 30 man-years of expertise in all related areas, such as Chemistry Manufacturing and Control CMC, including formulation development and IP issues. Services are customised to fit your project objectives, timelines and budget.

 For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com

 10.07.2020

 March 25, 2020, Basel, Switzerland. Guido Bossi, Managing Director of Orphanion announced that Orphanion is strengthening and up-dating its offerings of Active Pharmaceutical Ingredinets APIs in times of COVID-19, specifically its portfolio of oligonucleotides. “The COVID-19 pandemic is a serious threat to public health worldwide. We, therefore, are enhancing our capabilities of the seamless access to the well-known immunostimulant oligonucleotide CPG7909. Based on our knowledge of the synthesis of oligonucleotides, Orphanion is able to offer CpG 7909 in multiple gram amounts from the shelf.”

 CpG oligonucleotides (ODNs) are synthetic ODNs that contain non-methylated CpG dinucleotide units in specific sequence contexts (CpG motifs). CpG 7909 and related compounds activate the Toll-like receptor 9 (TLR9), leading to strong immunostimulatory effects and is a ligand of choice for human TLR9. Originally developed for the treatment of cancer, CpG 7909 found several pharmaceutical applications and is under development as an adjuvant for vaccines against cancer and infectious diseases.

 Orphanion can provide the CpG 7909 as non-GMP material from the shelf, with a purity of >95% for research and preclinical applications. CpG 7909, manufactured according to cGMP, or different CpG motifs, like CpG 1018,  or even dedicated conjugates will be provided and/or manufactured on request. In this context, the synthesis of reference material with high purity, or impurity markers (N-1, N-2…) may also be provided on request.

 Orphanion will continue its efforts to provide highest quality combined with competitive pricing of its CpG ODN products in order to make a small contribution to the development of effective therapies which can help to combat the present COVID-19 unprecedented pandemic.

 Swiss-based Orphanion supports small to mid-sized biotech and pharma companies with customized development and procurement services to optimize the growing sales potential for niche pharmaceuticals, orphan drugs and Oligonucleotides.

 You are invited to contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com for more detailed information.

 25.03.2020

 January 14, 2020, Basel, Switzerland. Guido Bossi, Managing Director of Orphanion announced that “Orphanion is expanding its portfolio into consulting services related to investment opportunities in pharma and biotech. “Subsequent to the service agreement with an international private equity firm concluded in the fall of 2019, Orphanion’s partners offer their extensive and intimate know-how and experience as well as an international network to investment firms, wishing to develop their healthcare and lifescience portfolio”.

 With some 75 man-years in senior executive positions of international operations of pharma and biotech companies as well as related service providers, Orphanion partners can rely on a comprehensive, hands-on management expertise and international network in Europe, the US and Asia.

 Swiss-based Orphanion supports small to mid-sized biotech and pharma companies with customized development and procurement services to optimize the growing sales potential for niche pharmaceuticals, orphan drugs and Oligonucleotides.

 You are invited to contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com for more detailed information.

 14.01.2020

 March 18, 2019, Basel, Switzerland and Erlanger, Kentucky, USA – Orphanion AG, a CRO/CMO that focuses on contract research and manufacturing services for niche active pharmaceutical ingredients (APIs), and LGM Pharma, LLC, a leader in API sourcing, warehousing and distribution services to the pharmaceutical and biotechnology industries, today announced that they have finalized a partnering agreement. Under the terms of the agreement, Orpharion’s specialty services, such as production of difficult-to-synthesize molecules for niche applications, will be available to LGM Pharma clients.

 Guido Bossi, Managing Director of Orphanion, commented, “Access to LGM’s extensive international experience and global clientele will enable Orphanion to extend our operational reach and broaden our service portfolio in niche market segments.”

 Prasad S. Raje, PhD, CEO of LGM Pharma, noted, “We welcome the opportunity to collaborate with Orphanion, which broadens the scope of API-related products and services we can offer our global customer base, especially in the areas of complex molecules and niche indications.“

 Further details of the agreement were not disclosed.

 About Orphanion
Orphanion is a Swiss-based CRO/CMO that supports small to mid-sized biotech and pharma companies with customized development and procurement services to optimize the growing sales potential for niche pharmaceuticals, orphan drugs and therapeutic oligonucleotides. This includes molecules that are difficult to synthesize, both from a process as well as a patent point-of-view. For more information on Orphanion and its services, please visit www.orphanion.com.

 About LGM Pharma
Headquartered in Erlanger, Kentucky with offices in Florida, New York and Israel, LGM Pharma is an innovation-driven, global leader in sourcing, warehousing and distribution of quality CGMP APIs to leading pharmaceutical and biotech companies. LGM specializes in streamlining API supply chain management through all phases of R&D, clinical development and commercialization, ensuring technical competence and adherence to clients’ timelines and specifications while providing expert guidance to navigate complex global regulatory submission strategies. For more information, visit lgmpharma.com.

 Contacts:

 Orphanion offers to its clients the supply of CpG 7909 in multiple gram amounts. CpG oligonucleotides (ODN’s) are synthetic ODN’s that contain non-methylated CpG dinucleotide units in specific sequence contexts (CpG motifs). CpG 7909 and related compounds activate the Toll-like receptor 9 (TLR9), leading to strong immunostimulatory effects and is a ligand of choice for human TLR9.

 CpG 7909 found several pharmaceutical applications, so it is originally being developed for the treatment of cancer but also under development as an adjuvant for vaccines against cancer and infectious diseases. More recently, conjugated versions, leading to a functionalized CpG oligodeoxynucleotide, shift into the focus of interest.

 

 Orphanion can provide the CpG 7909 as non-GMP material from shelf, with a purity of >85% for research and preclinical applications.

 

 CpG 7909, manufactured according to CGMP, or different CpG motifs like CpG 1018, or even dedicated conjugates will be provided/manufactured on request. In this context, the synthesis of reference material with high purity, or reference impurities (N-1, N-2...) are may also be provided on request.

 

 Orphanion will continue its efforts to provide highest quality combined with competitive pricing on its CpG ODN products.

 

For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com.

 Zürich, Switzerland, June 24, 2016. Swiss-based service provider to the pharma and biotech industries Orphanion AG, and A. Baur & Co. (Pvt.) Ltd. and Baur Asia Pte. Ltd. , a leading diversified group of companies based in Colombo, Sri Lanka and Singapore, today announced a comprehensive partnership encompassing the consumer, healthcare, animal health, agrochemical and nutritional sectors.

 “With the conclusion of a recent milestone agreement with Baur&Co. Ltd., Orphanion is expanding its international operations towards Asia. I am truly delighted about the alliance with Baur&Co to develop and market innovative new product solutions for patients and clients in south-east Asia”, Fritz Müller, Orphanion’s Chairman stated.

 

 Lakshman Niyangoda, Chief Executive Officer of A. Baur & Co. highlighted that “This partnership is in line with the long tradition of our company founded in 1897 to expand its portfolio of representing leading Swiss companies in the fastest growing markets in Asia.

 

 Local infrastructure and experience in the region allow our partners to focus on their own core expertise and reduce any regional risks by avoiding high costs of regional offices and recruitment.

 

 With Baurs you have a regional office with knowledge of the region and defining regions is another important factor. Often regions are created on a geographical basis without considering important factors such as cultural, administrative, political and economic differences. The world is neither truly local nor global

 

 Many SMEs have a range of innovative products of superior quality with good potential for the Asian markets. Many companies do not have the required know how to effectively and successfully promote their products in Asia

 

 Baurs - as your partner in Asia – allows you to concentrate on your core competence and at the same time be present in the region without having to invest in people or infrastructure.

 

 Baurs builds on a long and successful manufacturing and trading history and experience of A. Baur& Co. (Pvt.) Ltd. (www.baurs.com) and Baur Asia Pte. Ltd. (www.baurasia.com) and quality and its Swiss tradition.”

 

 Orphanion supports small to mid-sized biotech and pharma companies with customized development and procurement services to optimize the growing sales potential for niche pharmaceuticals and orphan drugs.

 

For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com.

For more information on A. Baur & Co. (Pvt.). Ltd. and Baur Asia Pte. Ltd., please visit www.baurasia.com or contact Lakshman Niyangoda, CEO, A. Baur & Co. (Pvt) Ltd, No. 5, Upper Chatham St, Colombo 1, Sri Lanka, tel +94 11 473 2670 or email lakshman.niyangoda@baurasia.com

 Basel, Switzerland, March 10, 2016. Swiss-based CRO/CMO Orphanion, provides project-tailored services focused on accelerating development and reducing time-to-market of niche drug products, including orphan drugs.

 

 Orphanion has recently become a member of the Swiss Biotech Association www.swissbiotech.org . “As Orphanion is expanding its operations in Switzerland and internationally, the Swiss Biotech Association provides an excellent community and platform to reach and communicate with its stake holders and potential clients”, notes Guido Bossi, Managing Director Orphanion.

 

 The Swiss Biotech Association represents the interest of the Swiss biotech sector and supports the entrepreneurship and creates value for biotech and service companies. In this context, Orphanion will attend The Swiss Biotech Day 2016 on April 12, 2016 in Basel http://swissbiotechday.ch/home/ and the Life Science Week, September 19-23, 2016 also in Basel, Switzerland http://www.basel-life-science-week.eu/2016/basel-life-science-week.html

 

Orphanion supports your business to optimize the growing sales potential for niche pharmaceuticals and orphan drugs – now and in the long-term.

 

For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com.

Basel, Switzerland, January 13, 2015. Swiss-based CRO/CMO Orphanion, provides project-tailored services focused on accelerating development and reducing time-to-market of niche drug products, including orphan drugs. The FDA announced January 8, 2015 it approved 41 new drugs in 2014, most in nearly two decades. The FDA also cited 2014 as the best year ever for approvals of drugs with a rare disease indication. The announcement also highlights that “…drugs that treat rare diseases are likely to continue as driving factors behind pharmaceutical growth in the years ahead…” according to the American Pharmacists Association.

 

Whether you are

• an emerging biotech company with urgent needs of API supply (e.g. for proof of concept studies)

• a small/mid-size pharma company with limited in-house production capacities or implementing a dual-site sourcing strategy,

• a custom research/manufacturing company seeking ways to optimize projects and timelines for your clients

 Guido Bossi, Managing Director Orphanion, is pleased to brief you on how we can help your Company create a smart and reliable API and intermediates supply chain.

Orphanion supports your business to optimize the growing sales potential for niche pharmaceuticals and orphan drugs – now and in the long-term.

 

For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com.

Please contact Guido Bossi, Managing Director, Orphanion to schedule a meeting and let him bring you up to-date on Orphanion's core competencies.

 

Email guido.bossi@orphanion.com cell +41 79 239'10'69"

For more information on Orphanion and its services, please visit www.orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or email guido.bossi@orphanion.com.

On June 20, 2014, Orphanion AG based in Basel Switzerland launches its operation as a service provider for orphan drug development to the pharmaceutical and biotechnology industries.

“Orphanion is a CRO/CMO that focuses on Contract Research and Manufacturing Services for pharmaceutical niche APIs, such as orphan drugs and related intermediates. In view of the steady growth in regulatory submissions and approvals for drugs targeting orphan diseases, Orphanion is uniquely positioned as partner in accelerating orphan drug development” notes Guido Bossi, Managing Director Orphanion.

In the USA, 17 products received orphan designation by the FDA in January 2014. 33% of all drugs approved by the FDA in 2013 were orphan drugs, and compound annual growth rate of the orphan drug market from 2001 to 2010 was 25.8% compared to 20.1% for a matched control group of non-orphan drugs.

Orphanion’s key expertise in Chemistry, Manufacturing and Control for active ingredients, intermediates and drug substances, is providing its clients with customized service packages, both in terms of reducing cost of goods as well as maintaining a competitive advantage. The team of senior managers and partners has extensive experience in drug development, project management and outsourcing activities with close ties to an international network of world standard companies in Europe and Asia.

Guido Bossi adds that “Now the drug development company has a choice – our business model offers options in terms of short- to long-term sourcing solutions at quality standards optimized for each project phase - from grams to multi-kilos of material. Orphanion will consider transaction structures ranging from supply and service agreements to royalty-based as well as out-licensing and partner arrangements. We are creative in finding ways to structure deals so that all parties obtain significant value.”

For more information on Orphanion and its services, please visit www.Orphanion.com or contact Guido Bossi, Managing Director, Orphanion AG, Tiergartenrain 3, CH-4054 Basel, Switzerland, Tel +41 79 230’10’69 or Email guido.bossi@Orphanion.com.